Company · CIK 0000874015 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
IONIS PHARMACEUTICALS INC · IONS
Insider activity reported against this company. All insider holders · Files at: AKCA, RGLS. On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 JForm 4 → | Sep 2, 8:32 pm EDT | C Frank BennettEVP, Chief Scientific Officer | 110 | $51.31 | $5,644 | 60,128 | — | |
| Aug 31, 2026 JForm 4 → | Sep 2, 8:22 pm EDT | Patrick R. O'NeilEVP CLO & General Counsel | 63 | $51.31 | $3,232 | 59,205 | — | |
| Aug 31, 2026 JForm 4 → | Sep 2, 8:22 pm EDT | Brett P MoniaChief Executive Officer, Director | 98 | $51.31 | $5,028 | 242,760 | — | |
| Aug 31, 2026 JForm 4 → | Sep 2, 8:22 pm EDT | Brian BirchlerEVP, Corp and Development Ops | 58 | $51.31 | $2,976 | 102,883 | — | |
| Jul 30, 2026 PForm 4 → | Jul 31, 4:42 pm EDT | Michael R HaydenDirector | 20,000 | $52.94 | $1,058,700 | 24,000 | +500% | |
| Jul 15, 2026 MForm 4 → | Jul 17, 5:12 pm EDT | Joan E HermanDirector | 5,220 | — | — | 51,306 | — | |
| Jul 15, 2026 MForm 4 → | Jul 17, 5:12 pm EDT | Spencer R BerthelsenDirector | 5,220 | — | — | 161,233 | — | |
| Jul 7, 2026 JForm 4 → | Jul 9, 7:26 pm EDT | C Frank BennettEVP, Chief Scientific Officer | 15,000 | — | — | 15,000 | — | 10b5-1 |
| Jul 7, 2026 SForm 4 → | Jul 9, 7:26 pm EDT | C Frank BennettEVP, Chief Scientific Officer | 20,536 | $84.95 | $1,744,623 | 0 | −100% | 10b5-1 |
| Jul 7, 2026 SForm 4 → | Jul 9, 6:07 pm EDT | Allene M. DiazDirector | 10,111 | $85.42 | $863,637 | 3,811 | −72.6% | 10b5-1 |
| Jul 7, 2026 MForm 4 → | Jul 9, 6:07 pm EDT | Allene M. DiazDirector | 10,111 | $47.11 | $476,329 | 13,922 | — | 10b5-1 |
| Jul 7, 2026 SForm 4 → | Jul 9, 6:07 pm EDT | Holly B. KordasiewiczEVP, Chief Development Officer | 362 | $84.30 | $30,517 | 22,096 | −1.61% | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 6, 6:49 pm EDT | Joseph Klein IIIDirector | 11,518 | $79.04 | $910,416 | 11,014 | −51.1% | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 6, 6:49 pm EDT | Joseph Klein IIIDirector | 11,518 | $39.94 | $460,029 | 22,532 | — | 10b5-1 |
| Jun 26, 2026 SForm 4 → | Jun 30, 5:48 pm EDT | Joseph BaroldiEVP, Chief Business Officer | 5,635 | $80.16 | $451,699 | 4,669 | −54.7% | 10b5-1 |
| Jun 26, 2026 MForm 4 → | Jun 30, 5:48 pm EDT | Joseph BaroldiEVP, Chief Business Officer | 5,635 | $49.19 | $277,181 | 10,304 | — | 10b5-1 |
| Jun 26, 2026 SForm 4 → | Jun 30, 5:48 pm EDT | Patrick R. O'NeilEVP CLO & General Counsel | 3,069 | $80.00 | $245,520 | 61,470 | −4.76% | 10b5-1 |
| Jun 26, 2026 SForm 4 → | Jun 30, 5:48 pm EDT | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | 26,000 | $81.05 | $2,107,196 | 77,114 | −25.2% | 10b5-1 |
| Jun 26, 2026 MForm 4 → | Jun 30, 5:48 pm EDT | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | 26,000 | $60.89 | $1,583,140 | 103,114 | — | 10b5-1 |
| Jun 25, 2026 SForm 4 → | Jun 26, 7:09 pm EDT | Eric SwayzeEVP Research | 10,602 | $79.18 | $839,492 | 21,759 | −32.8% | 10b5-1 |
| Jun 24, 2026 SForm 4 → | Jun 26, 7:09 pm EDT | Brett P MoniaChief Executive Officer, Director | 85,637 | $79.70 | $6,825,524 | 245,571 | −25.9% | 10b5-1 |
| Jun 24, 2026 MForm 4 → | Jun 26, 7:09 pm EDT | Brett P MoniaChief Executive Officer, Director | 85,637 | $46.72 | $4,000,766 | 295,571 | — | 10b5-1 |
| Jun 15, 2026 SForm 4 → | Jun 16, 5:26 pm EDT | Spencer R BerthelsenDirector | 8,000 | $73.49 | $587,920 | 156,013 | −4.88% | 10b5-1 |
| Jun 15, 2026 MForm 4 → | Jun 16, 5:26 pm EDT | Spencer R BerthelsenDirector | 8,000 | $24.42 | $195,360 | 164,013 | — | 10b5-1 |
| Jun 12, 2026 SForm 4 → | Jun 16, 5:26 pm EDT | Holly B. KordasiewiczEVP, Chief Development Officer | 60,846 | $73.41 | $4,466,428 | 22,458 | −73.0% | 10b5-1 |
| Jun 12, 2026 MForm 4 → | Jun 16, 5:26 pm EDT | Holly B. KordasiewiczEVP, Chief Development Officer | 60,846 | $53.97 | $3,283,664 | 83,304 | — | 10b5-1 |
| Jun 1, 2026 SForm 4 → | Jun 3, 5:34 pm EDT | Spencer R BerthelsenDirector | 8,000 | $75.67 | $605,360 | 156,013 | −4.88% | 10b5-1 |
| Jun 1, 2026 MForm 4 → | Jun 3, 5:34 pm EDT | Spencer R BerthelsenDirector | 8,000 | $24.42 | $195,360 | 164,013 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 AForm 4 → | Jul 17, 5:13 pm EDT | Peter N ReikesDirector | 3,399 | — | — | 3,399 | — | |
| Jul 15, 2026 AForm 4 → | Jul 17, 5:13 pm EDT | Ludwig HantsonDirector | 3,399 | — | — | 3,399 | — | |
| Jul 15, 2026 MForm 4 → | Jul 17, 5:12 pm EDT | Joan E HermanDirector | 5,220 | — | — | 2,301 | — | |
| Jul 15, 2026 MForm 4 → | Jul 17, 5:12 pm EDT | Spencer R BerthelsenDirector | 5,220 | — | — | 2,301 | — | |
| Jul 7, 2026 JForm 4 → | Jul 9, 7:26 pm EDT | C Frank BennettEVP, Chief Scientific Officer | 15,000 | — | — | 12,109 | — | 10b5-1 |
| Jul 7, 2026 MForm 4 → | Jul 9, 6:07 pm EDT | Allene M. DiazDirector | 10,111 | — | — | 0 | — | 10b5-1 |
| Jul 1, 2026 AForm 4 → | Jul 6, 6:50 pm EDT | Michael J. YangDirector | 7,670 | — | — | 9,451 | — | |
| Jul 1, 2026 AForm 4 → | Jul 6, 6:50 pm EDT | Joseph LoscalzoDirector | 7,670 | — | — | 7,521 | — | |
| Jul 1, 2026 AForm 4 → | Jul 6, 6:49 pm EDT | Joan E HermanDirector | 7,670 | — | — | 7,521 | — | |
| Jul 1, 2026 AMForm 4 → | Jul 6, 6:49 pm EDT | Joseph Klein IIIDirector | 19,188 | — | — | 16,277 | — | 10b5-1 |
| Jul 1, 2026 AForm 4 → | Jul 6, 6:45 pm EDT | Michael R HaydenDirector | 7,670 | — | — | 12,198 | — | |
| Jul 1, 2026 AForm 4 → | Jul 6, 6:44 pm EDT | Allene M. DiazDirector | 7,670 | — | — | 7,521 | — | |
| Jul 1, 2026 AForm 4 → | Jul 6, 6:44 pm EDT | Spencer R BerthelsenDirector | 7,670 | — | — | 7,521 | — | |
| Jun 26, 2026 MForm 4 → | Jun 30, 5:48 pm EDT | Joseph BaroldiEVP, Chief Business Officer | 5,635 | — | — | 0 | — | 10b5-1 |
| Jun 26, 2026 MForm 4 → | Jun 30, 5:48 pm EDT | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | 26,000 | — | — | 26,000 | — | 10b5-1 |
| Jun 24, 2026 MForm 4 → | Jun 26, 7:09 pm EDT | Brett P MoniaChief Executive Officer, Director | 85,637 | — | — | 99,872 | — | 10b5-1 |
| Jun 15, 2026 MForm 4 → | Jun 16, 5:26 pm EDT | Spencer R BerthelsenDirector | 8,000 | — | — | 0 | — | 10b5-1 |
| Jun 12, 2026 MForm 4 → | Jun 16, 5:26 pm EDT | Holly B. KordasiewiczEVP, Chief Development Officer | 60,846 | — | — | 0 | — | 10b5-1 |
| Jun 4, 2026 AForm 4 → | Jun 8, 4:59 pm EDT | Peter N ReikesDirector | 10,753 | — | — | 10,753 | — | |
| Jun 4, 2026 AForm 4 → | Jun 8, 4:59 pm EDT | Ludwig HantsonDirector | 10,753 | — | — | 10,753 | — | |
| Jun 1, 2026 MForm 4 → | Jun 3, 5:34 pm EDT | Spencer R BerthelsenDirector | 8,000 | — | — | 8,000 | — | 10b5-1 |
Filed by this entity as an insider elsewhere — common stock
No reported common-stock activity in this period.
Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.